

November 2007

Volume 12 · Numbers 21/22

pp. 891–994

**Cover Story**

In this month's Keynote Review, John Desjarlais and co-authors give us an engineer's perspective on how to optimise antibodies in order for them to engage more efficiently with the immune system. This interaction with the body's immune system is a prerequisite for the therapeutic success of monoclonal antibodies in tumour treatment. The review informs about the latest strategies of improving the interaction of antibodies with the FC gamma receptor (FcγR) on target cells and discusses open questions such as how to identify the optimal FcγR selectivity and affinity profiles. Despite the lack of knowledge on some aspects of these issues, the success of monoclonal antibodies for cancer treatment will hopefully ensure that these gaps will be filled in the near future.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

898 **Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective**

John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky and Seung Y. Chu

GENE TO SCREEN

911 **Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery**

Shen Hu, Yun Yen, David Ann and David T. Wong

917 **Kinase packing defects as drug targets**

Alejandro Crespo and Ariel Fernández

INFORMATICS

924 **Achieving confidence in mechanism in drug discovery and development**

Zach Pitluk and Iya Khalil

POST SCREEN

931 **DNA fragmentation-based combinatorial approaches to soluble protein expression. Part I. Generating DNA fragment libraries**

Chrisostomos Prodromou, Renos Savva and Paul C. Driscoll

939 **DNA fragmentation based combinatorial approaches to soluble protein expression. Part II: Library expression, screening and scale-up**

Renos Savva, Chrisostomos Prodromou and Paul C. Driscoll

948 **Topography-biased compound library design: the shape of things to come?**

Irini Akritopoulou-Zanze, James T. Metz and Stevan W. Djuric

953 **The impact of pharmacogenetics on the development and use of antipsychotic drugs**

Gavin P. Reynolds

960 **Cost-effectiveness analysis: should it be required for drug registration and beyond?**

Renée J. Goldberg Arnold

966 **Therapeutic potential of antifungal plant and insect defensins**

Karin Thevissen, Hans-Henrik Kristensen, Bart P.H.J. Thomma, Bruno P.A. Cammue and Isabelle E.J.A. François

972 **MCH-R1 antagonists: what is keeping most research programs away from the clinic?**

José L. Méndez-Andino and John A. Vos

980 **Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery**

Dominique J. Pepper, Graeme A. Meintjes, Helen McIlleron and Robert J. Wilkinson

ERRATUM

990 **Erratum: Rescuing CD4+ CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy**